Skip to Content

Posts tagged with "Drug Development"

  • Drug Development

    Idiocy On Drug Research Costs

    Here’s a piece from the Center for Economic and Policy Research that claims to have the whole high-drug-price problem figured out. It’s “incredibly inefficient research”, just so you know. How does the CEPR know, you ask? They do a comparison of the costs of research (as provided by the Center for the Study of Drug Developm… Read More
  • Cancer

    Another Funny-Looking Structure Comes Through

    Here’s one that I certainly wouldn’t have thought about doing. This recent paper in ACS Medicinal Chemistry Letters describes changing the substituents off the core of a PAK1 inhibitor. Nothing too interesting about that, you’d think: the inhibitor itself is one of your standard-looking kinase inhibitor sausage strings of heteroar… Read More
  • Cancer

    Looking Back at Sutent’s Development: Problems or Not?

    Here’s a report on the preclinical development of Sutent (sunitinib). The authors did a retrospective analysis of all the published studies, and found a number of problems. It should be noted that these are definitely not limited to just this drug – in fact, the authors are explicitly extending their conclusion to a lot of… Read More
  • Drug Development

    Loosening Things Up in Japan

    Japan is going to try opening up its medical approval process for regenerative medicine (no doubt with an eye on its aging population). Regulatory changes that started taking effect last fall now allow companies to get conditional approval based on smaller trials, and these apparently don’t even have to be placebo-controlled. The products can… Read More
  • Cancer

    A Biotech Education, In Progress

    Peter Thiel is worth paying some attention to. And it’s not just because he’s a wealthy venture capitalist – his views on pharma and biotech research are worth noting because he’s an excellent example of an intelligent, motivated outsider, someone with a strong technical background who’s approaching drug discovery de n… Read More
  • Academia (vs. Industry)

    Magic Open Source Savings Await

    I’ve never known quite what to make of the “open source pharma” idea. I know that there are a lot of people working on things in this area, and that there’s a lot of interest. But as someone who does drug discovery for a living, I can’t quite see how it can work. And I’m… Read More
  • Drug Development

    Picturing A Drug Effort’s Progress

    Lead optimization – that’s what people think about when they think about medicinal chemistry, assuming that they ever do. “Lead op” is where compounds get whipped into drug candidates, through iterative rounds of synthesis and testing, and if that sounds straightforward, then you haven’t had a chance to try it: Given t… Read More
  • Clinical Trials

    The Wildly Unlikely Return of TGN1412

    You may be familiar with the bizarre story of TGN1412, an immunotherapy developed (briefly) by a small German company called TeGenero in 2006. This led to the infamous Phase I incident in England where a set of six volunteers were dosed at fifteen-minute intervals, but right after the last one got the injection, the first… Read More
  • Cancer

    ABT-199 Nears Its Finish Line

    A couple of years back, AbbVie ran into an unusual problem in the clinic. Their Bcl ligand, ABT-199, was working a bit too well, and killing off so many leukemia cells that the resulting cellular debris was causing kidney trouble in some patients. The company immediately started working on clinical protocols to get things restarted… Read More
  • Drug Development

    Modeling the Rats, Who Model the Humans

    When you get down to it, one of the biggest problems in drug discovery is that there is (in most cases) no alternative but doing things the hard way. If you want to find out if your drug is going to work for a given disease, there’s no other way to be sure than to… Read More